Literature DB >> 19950107

Detecting qualitative interaction: a Bayesian approach.

Emine Ozgür Bayman1, Kathryn Chaloner, Mary Kathryn Cowles.   

Abstract

Differences in treatment effects between centers in a multi-center trial may be important. These differences represent treatment by subgroup interaction. Peto defines qualitative interaction (QI) to occur when the simple treatment effect in one subgroup has a different sign than in another subgroup: this interaction is important. Interaction where the treatment effects are of the same sign in all subgroups is called quantitative and is often not important because the treatment recommendation is identical in all cases. A hierarchical model is used here with exchangeable mean responses to each treatment between subgroups. The posterior probability of QI and the corresponding Bayes factor are proposed as a diagnostic and as a test statistic. The model is motivated by two multi-center trials with binary responses. The frequentist power and size of the test using the Bayes factor are examined and compared with two other commonly used tests. The impact of imbalance between the sample sizes in each subgroup on power is examined, and the test based on the Bayes factor typically has better power for unbalanced designs, especially for small sample sizes. An exact test based on the Bayes factor is also suggested assuming the hierarchical model. The Bayes factor provides a concise summary of the evidence for or against QI. It is shown by example that it is easily adapted to summarize the evidence for 'clinically meaningful QI,' defined as the simple effects being of opposite signs and larger in absolute value than a minimal clinically meaningful effect. (c) 2009 John Wiley & Sons, Ltd.

Mesh:

Year:  2010        PMID: 19950107     DOI: 10.1002/sim.3787

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  On Bayesian methods of exploring qualitative interactions for targeted treatment.

Authors:  Wei Chen; Debashis Ghosh; Trivellore E Raghunathan; Maxim Norkin; Daniel J Sargent; Gerold Bepler
Journal:  Stat Med       Date:  2012-06-26       Impact factor: 2.373

Review 2.  Considerations when assessing heterogeneity of treatment effect in patient-centered outcomes research.

Authors:  Catherine R Lesko; Nicholas C Henderson; Ravi Varadhan
Journal:  J Clin Epidemiol       Date:  2018-04-11       Impact factor: 6.437

3.  Designing and analyzing clinical trials for personalized medicine via Bayesian models.

Authors:  Chuanwu Zhang; Matthew S Mayo; Jo A Wick; Byron J Gajewski
Journal:  Pharm Stat       Date:  2021-01-19       Impact factor: 1.894

Review 4.  Subgroup analyses in confirmatory clinical trials: time to be specific about their purposes.

Authors:  Julien Tanniou; Ingeborg van der Tweel; Steven Teerenstra; Kit C B Roes
Journal:  BMC Med Res Methodol       Date:  2016-02-18       Impact factor: 4.615

5.  Bayesian methods to determine performance differences and to quantify variability among centers in multi-center trials: the IHAST trial.

Authors:  Emine O Bayman; Kathryn M Chaloner; Bradley J Hindman; Michael M Todd
Journal:  BMC Med Res Methodol       Date:  2013-01-16       Impact factor: 4.615

6.  Genetics of adverse reactions to haloperidol in a mouse diallel: a drug-placebo experiment and Bayesian causal analysis.

Authors:  James J Crowley; Yunjung Kim; Alan B Lenarcic; Corey R Quackenbush; Cordelia J Barrick; Daniel E Adkins; Ginger S Shaw; Darla R Miller; Fernando Pardo-Manuel de Villena; Patrick F Sullivan; William Valdar
Journal:  Genetics       Date:  2013-11-15       Impact factor: 4.562

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.